septerna - Search News

Order byBest matchMost fresh

Novo Nordisk Inks A Major Obesity Deal

Top News

Impacts

Novo Nordisk and Septerna Strike $2.2 Billion Deal to Develop Obesity Pills

The deal with U.S. biotech Septerna will see the companies develop pills to treat obesity, type 2 diabetes and other cardiometabolic diseases.

· 8h · on MSN

· 1d · on MSN

Novo Nordisk, Septerna Agree $2.2 Billion Obesity Pill Deal

· 1d · on MSN

Novo Nordisk in pact with Septerna for oral obesity drugs

Novo Nordisk and Septerna Collaborate on Oral Medicines for Obesity and Other Diseases

Under the terms of the agreement, Septerna is eligible to receive around $2.2 billion from Novo Nordisk, including over $200 million in upfront and near-term milestone payments.

· 8h

Ignore The Noise - Novo Nordisk Is A Clear Buy

STAT · 1d

Novo Nordisk strikes deal with Septerna to develop obesity pills

Novo Nordisk, Septerna sign $2.2B deal to develop weight-loss pill

Pharmaceutical giant Novo Nordisk (NVO) inks a $2.2 billion deal with biotech company Septerna (SEPN) to develop a GLP-1 weight-loss drug in the form of an oral pill. Septerna's stock is skyrocketing by over 60% in Wednesday's pre-market session (at the time of this video's posting).